Payment overview · 2025
General Payments
$1,553.16
79 reported records · 19 companies
Healthcare provider profile · identity verified
Joseph E Cesanek, MD
Allopathic & Osteopathic Physicians|Family Medicine · WIND GAP, PA · NPI 1053327106
Verified facts
What the public records show
CMS Open Payments records show Joseph E Cesanek, MD received $1,553.16 in general payments during 2025 across 79 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 528 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 528 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $338.72 | 21.8% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $278.28 | 17.9% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $208.70 | 13.4% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $157.06 | 10.1% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.51 | 5.6% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.26 | 4.9% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.78 | 4.4% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $56.95 | 3.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.61 | 3.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.87 | 3.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.41 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.39 | 1.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.34 | 1.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.72 | 1.3% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $19.68 | 1.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.11 | 1.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $19.08 | 1.2% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $17.74 | 1.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.95 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,553.16 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $264.23 | 15 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $233.21 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $142.31 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.97 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.39 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $86.22 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.57 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $80.53 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $76.26 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.80 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $67.78 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $57.25 | 3 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $56.95 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.61 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.61 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.75 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.87 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $17.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 528 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 144 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 29 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
528 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
90 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
528 | 70 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 976 | 232 |
| Levothyroxine Sodium | Levothyroxine Sodium | 735 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 558 | 125 |
| Eliquis | Apixaban | 528 | 70 |
| Gabapentin | Gabapentin | 528 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 503 | 103 |
| Alprazolam | Alprazolam | 441 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 406 | 92 |
| Metformin Hcl | Metformin Hcl | 403 | 92 |
| Lisinopril | Lisinopril | 386 | 96 |
| Furosemide | Furosemide | 378 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 374 | 74 |
| Omeprazole | Omeprazole | 343 | 87 |
| Potassium Chloride | Potassium Chloride | 333 | 48 |
| Losartan Potassium | Losartan Potassium | 292 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 274 | 73 |
| Sertraline Hcl | Sertraline Hcl | 268 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 232 | 51 |
| Allopurinol | Allopurinol | 229 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 227 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 59 |
| Lorazepam | Lorazepam | 221 | 44 |
| Montelukast Sodium | Montelukast Sodium | 216 | 51 |
| Simvastatin | Simvastatin | 208 | 55 |
| Valsartan | Valsartan | 196 | 46 |
| Trazodone Hcl | Trazodone Hcl | 184 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 180 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 171 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 171 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 170 | 33 |
| Famotidine | Famotidine | 165 | 35 |
| Tramadol Hcl | Tramadol Hcl | 164 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 28 |
| Nystatin | Nystatin | 158 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 155 | 43 |
| Mirtazapine | Mirtazapine | 154 | 32 |
| Jardiance | Empagliflozin | 144 | 29 |
| Spironolactone | Spironolactone | 142 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 17 |
| Celecoxib | Celecoxib | 140 | 30 |
| Buspirone Hcl | Buspirone Hcl | 135 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 28 |
| Glimepiride | Glimepiride | 117 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 111 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | 17 |
| Naproxen | Naproxen | 107 | 43 |
| Ezetimibe | Ezetimibe | 106 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 26 |
| Xarelto | Rivaroxaban | 102 | 21 |
| Donepezil Hcl | Donepezil Hcl | 97 | 16 |
| Baclofen | Baclofen | 96 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 19 |
| Clonazepam | Clonazepam | 92 | 14 |
| Trulicity | Dulaglutide | 90 | 13 |
| Bupropion Xl | Bupropion Hcl | 89 | 18 |
| Olanzapine | Olanzapine | 86 | 17 |
| Carvedilol | Carvedilol | 85 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 85 | 38 |
| Torsemide | Torsemide | 85 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 17 |
| Meclizine Hcl | Meclizine Hcl | 77 | 28 |
| Meloxicam | Meloxicam | 77 | 19 |
| Latanoprost | Latanoprost | 74 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 73 | 16 |
| Levetiracetam | Levetiracetam | 72 | 14 |
| Pregabalin | Pregabalin | 72 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 53 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 70 | 12 |
| Finasteride | Finasteride | 69 | 15 |
| Amoxicillin | Amoxicillin | 68 | 34 |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 66 | suppressed |
| Cephalexin | Cephalexin | 61 | 30 |
| Atenolol | Atenolol | 60 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 14 |
| Midodrine Hcl | Midodrine Hcl | 59 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 58 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 57 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | suppressed |
| Hydrocortisone | Hydrocortisone | 56 | 15 |
| Prednisone | Prednisone | 56 | 26 |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Primidone | Primidone | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Methocarbamol | Methocarbamol | 50 | 15 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Ibuprofen | Ibuprofen | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 47 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 42 | 16 |
| Glipizide Er | Glipizide | 41 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 12 |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Irbesartan | Irbesartan | 39 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 37 | 33 |
| Colchicine | Colchicine | 37 | 11 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Nystop | Nystatin | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 13 |
| Insulin Aspart Flexpen | Insulin Aspart | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 16 |
| Jentadueto | Linagliptin/Metformin Hcl | 25 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 25 | 25 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Klor-Con 10 | Potassium Chloride | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | suppressed |
| Oxycontin | Oxycodone Hcl | 23 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Jantoven | Warfarin Sodium | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Nateglinide | Nateglinide | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Ramipril | Ramipril | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Ulticare Safety Pen Needle | Pen Needle, Diabetic, Safety | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Alphagan P | Brimonidine Tartrate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fetzima | Levomilnacipran Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,553.16 · 79 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COMIRNATY, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, LOREEV XR, MOUNJARO, NEFFY, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TONMYA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Vest Therapy Und, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error